Details of the Drug-Related molecule(s) Expression Atlas

General Information of Drug (ID: DMEZ2KH)

Drug Name

Ocrelizumab Drug Info

Synonyms

Ocrelizumab (USAN); Ocrelizumab (genetical recombination); Ocrelizumab (genetical recombination) (JAN)

Indication

Disease Entry	ICD 11	Status	REF
Diffuse large B-cell lymphoma	2A81	Approved	[1]
Multiple sclerosis	8A40	Approved	[2]

Cross-matching ID

Molecule(s) Related to This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Leukocyte surface antigen Leu-16 (CD20)	TTUE541	CD20_HUMAN	Not Available	[3]

------------------------------------------------------------------------------------

The Expression Level of Molecule(s) in Normal Tissue of Major ADME-Related Organs

Molecule	Molecule Type	Gene Name	Liver	Colon	Kidney	Small Intestine
Leukocyte surface antigen Leu-16 (CD20)	DTT	MS4A1	5.859	6.999	5.828	5.586

Molecule Expression Atlas in Normal Tissue of Major ADME-related organs

The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue

The Studied Disease

Diffuse large B-cell lymphoma

ICD Disease Classification

2A81

Molecule Name	Molecule Type	Gene Name	p-value	Fold-Change	Z-score
Leukocyte surface antigen Leu-16 (CD20)	DTT	MS4A1	4.00E-02	0.25	0.56

Molecular Expression Atlas between Disease Section and Healthy Individual Tissue

References

1	2017 FDA drug approvals.Nat Rev Drug Discov. 2018 Feb;17(2):81-85.
2	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2018
3	Emerging drugs for rheumatoid arthritis. Expert Opin Emerg Drugs. 2008 Mar;13(1):175-96.